Search | IOVS | ARVO Journals

Access Provided By:
MIT Libraries

Forgot password?

Create an Account

View

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract May 2006

Subconjunctival Budesonide or Budesonide–Poly(lactide) Microparticles Do Not Elevate Intraocular Pressure or Induce Lens Opacities in the Rabbit Model

E.R. Escobar; N.P. Cheruvu; G. Zhan; C.B. Toris; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):4493.

ARVO Annual Meeting Abstract May 2006

Administration of Anecortave Acetate in a Finite Element Physiologic Ocular Pharmacokinetic Model

A.L. Weiner; P.J. Missel; J.E. Chastain; Y. Yaacobi; A.K. Mitra; U.B. Kompella; V. Kansara; S. Duvvuri; A. Amrite; N. Cheruvu

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5084.

ARVO Annual Meeting Abstract May 2006

Transscleral Delivery of Lens Epithelium Derived Growth Factor (LEDGF/p75) and p52

A.C. Amrite; P. Malik; T. Shinohara; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):5117.

ARVO Annual Meeting Abstract May 2006

AQ4N, a Cytotoxic Prodrug, Inhibits Proliferation and VEGF Secretion in Retinal Cells

S. Raghava; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):2884.

ARVO Annual Meeting Abstract May 2006

Effect of Eye Pigmentation and Diabetes on Transscleral Drug Delivery

N.P. Cheruvu; A.C. Amrite; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2006; 47(13):4470.

ARVO Annual Meeting Abstract May 2005

Single Periocular Administration of Celecoxib–PLGA Microparticles Reduces Retinal PGE2 Secretion, VEGF Expression, and Vascular Leakage in Diabetic Rats

A.C. Amrite; N.P. S. Cheruvu; D.S. Dhanda; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):449.

ARVO Annual Meeting Abstract May 2005

Transscleral Transport: Barrier Properties of Sclera, Choroid–Tapetum, and Retinal Pigment Epithelium

N.P. S. Cheruvu; E.R. Escobar; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2005; 46(13):5390.

ARVO Annual Meeting Abstract May 2004

Subconjunctivally administered celecoxib–PLGA microparticles sustain retinal drug levels and alleviate diabetes–induced retinal oxidative stress

S.P. Ayalasomayajula; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3957.

ARVO Annual Meeting Abstract May 2004

Microparticles but not nanoparticles are retained in the subconjunctival space at 2–months post–administration.

A.C. Amrite; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):5067.

ARVO Annual Meeting Abstract May 2004

Celecoxib, a selective COX–2 inhibitor, inhibits diabetes–induced retinal PGE2 secretion

R.N. Aravalli; S.P. Ayalasomayajula; A.C. Amrite; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2004; 45(13):3580.

ARVO Annual Meeting Abstract May 2003

In Vitro Transport and Hydrolysis of Bimatoprost in Bovine Cornea

A. Kriatchko; G. Zhan; N. Cheruvu; S.P. Ayalasomayajula; C.B. Camras; R.V. Patil; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4422.

ARVO Annual Meeting Abstract May 2003

Retinal Celecoxib Delivery Following Subconjunctival Administration is 39-Fold Higher Compared to Systemic Administration

S.P. Ayalasomayajula; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4444.

ARVO Annual Meeting Abstract May 2003

Choroid-Tapetum Poses a Significant Barrier to Transscleral Transport and the Retinal Accumulation Following Subconjunctival Administration Does not Depend on Drug Lipophilicity

N.P. Cheruvu; S.P. Ayalasomayajula; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4447.

ARVO Annual Meeting Abstract May 2003

Nano- and Micro-Particles Reach Retina Following Systemic but Not Subconjunctival Administration

A.C. Amrite; S.P. Ayalasomayajula; U.B. Kompella

Invest. Ophthalmol. Vis. Sci.. 2003; 44(13):4449.

Advertisement